Treatment of rifampin-resistant and multidrug-resistant tuberculosis in pregnant women is more complicated since little is known about the safety of second-line antituberculosis drugs during pregnancy and lactation. Drug-resistant tuberculosis, not having many options in the past, has been treated with regimens that include drugs with teratogenic potentials, such as thioamides and second-line injectables. Currently, there are new oral drugs, including bedaquiline, for the treatment of drugresistant disease; however, the safety of bedaquiline during pregnancy and lactation has not been satisfactorily demonstrated so far. We report the first case in Mexico treated with a regimen that includes bedaquiline for multidrug-resistant tuberculosis during pregnancy, with favorable results, and without maternal-fetal complications.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.